Case Details
- Case Title: China Medical Technologies, Inc. (in liquidation) & Anor v Wu Xiaodong & Anor
- Citation: [2018] SGHC 178
- Court: High Court of the Republic of Singapore
- Judgment Date: 13 August 2018
- Proceedings: Suit No 1180 of 2017; Summonses Nos 5689 of 2017 and 878 of 2018
- Judge: Audrey Lim JC
- Hearing Dates: 23 March 2018; 16 May 2018; 13 August 2018 (judgment reserved)
- Plaintiffs/Applicants: (1) China Medical Technologies, Inc. (in liquidation) (2) CMED Technologies Ltd
- Defendants/Respondents: (1) Wu Xiaodong (2) Bi Xiaoqiong (in her personal capacity and as trustee of the Xiao Qiong Bi Trust and the Alisa Wu Irrevocable Trust)
- Legal Area(s): Civil Procedure; Injunctions; Mareva injunctions; Court’s power to grant Mareva injunction in aid of foreign court proceedings
- Key Statutory Provision(s) Referenced: Section 4(10) of the Civil Law Act (Cap 43, 1999 Rev Ed)
- Other Statutes Referenced (as per metadata): British Columbia Law and Equity Act 1979; Civil Jurisdiction and Judgments Act 1982; Federal Courts Act 1985
- Cases Cited (as per metadata): [2018] SGCA 27; [2018] SGHC 178
- Judgment Length: 46 pages; 14,768 words
Summary
In China Medical Technologies, Inc. (in liquidation) & Anor v Wu Xiaodong & Anor [2018] SGHC 178, the High Court considered whether Singapore has the power to grant a Mareva injunction in aid of foreign court proceedings. The plaintiffs, a Cayman Islands company in liquidation and its wholly-owned subsidiary, had commenced proceedings in Hong Kong and obtained a worldwide Mareva injunction there. They then sued in Singapore and sought a Mareva injunction against the defendants’ assets in Singapore, even though the substantive dispute was intended to be litigated in Hong Kong.
The court held that the Singapore court does have power under s 4(10) of the Civil Law Act to grant interim injunctive relief in aid of foreign proceedings, provided certain conditions are satisfied. The court emphasised that the existence of in personam jurisdiction over the defendant is a critical threshold, but not the only one. The plaintiffs also had to show a “good arguable case” on the merits and a “real risk” that the defendant would dissipate assets within Singapore to frustrate the foreign proceedings.
Applying these principles, the court analysed the evidence against each defendant and assessed whether the factual allegations and tracing of funds supported the required level of arguability, and whether the risk of dissipation was sufficiently established. The decision is significant for practitioners because it clarifies the scope of s 4(10) and the practical approach Singapore courts take when asked to grant Mareva relief to support foreign litigation.
What Were the Facts of This Case?
The first plaintiff (“P1”) was a public company incorporated in the Cayman Islands in 2004, and the second plaintiff (“P2”) was its wholly-owned subsidiary. In the period around February 2007 and October 2008, P1 and P2 acquired medical technologies for approximately US$521.8 million from Supreme Well Investments Limited (“SW”) and SW’s subsidiary. After P1 was wound up in July 2012, liquidators investigated P1’s affairs and concluded that the technologies purchased were substantially worthless and that SW was a sham entity controlled by P1’s former management, including the first defendant, Wu Xiaodong (“Wu”).
On the plaintiffs’ case, the alleged fraud (“the Fraud”) involved fraudulent misappropriation of the US$521.8 million by former management and associates. The plaintiffs alleged that Wu and other directors orchestrated and participated in the Fraud. They further alleged that funds transferred from P1 and P2 to SW were subsequently distributed to bank accounts of parties described as “SW Payees”, apparently associated with or controlled by Wu and/or his associates. Those funds were then transferred again to “Further SW Payees”, which included Wu and the second defendant, Bi Xiaoqiong (“Bi”).
Bi married Wu in 1995 and entered into a divorce agreement in 2012. Bi’s position was that although the divorce agreement was entered into, she and Wu had been separated since 2001. This relationship history became relevant to the plaintiffs’ narrative about how assets might be held, moved, or protected through family and trust structures.
Procedurally, P1 commenced a first action in the Hong Kong High Court on 1 August 2013 (“first HK suit”) against Wu and four others, alleging, among other things, breach of fiduciary duties, breach of trust, fraud, conspiracy, knowing receipt, dishonest assistance, and money had and received. Later, on 23 December 2016, P1 and P2 commenced a second action in the Hong Kong High Court (“second HK suit”) against Wu, Bi, and 21 others, adding further claims. The plaintiffs intended to consolidate the first and second HK suits. The writ in the second HK suit was served on Bi’s solicitors on 27 November 2017, and on 11 December 2017 the Hong Kong court granted P1 and P2 a worldwide Mareva injunction against Wu and Bi in the second HK suit, including assets in Singapore.
What Were the Key Legal Issues?
The central legal issue was whether the Singapore High Court has the power to grant a Mareva injunction in aid of foreign court proceedings under s 4(10) of the Civil Law Act. The plaintiffs’ primary purpose in commencing the Singapore suit was to obtain Mareva relief to prevent dissipation of assets in Singapore that were already subject to the Hong Kong Mareva injunction. The defendants challenged the court’s power to grant such relief, arguing that Singapore should not provide interim enforcement support for foreign proceedings where the substantive dispute is to be determined elsewhere.
A second set of issues concerned the substantive requirements for Mareva relief. Even if the court had the relevant power, the plaintiffs still had to establish (i) a “good arguable case” on the merits against the defendants, and (ii) a “real risk” that the defendants would dissipate assets within the jurisdiction to frustrate the enforcement of any eventual judgment or order. The court therefore had to assess the strength of the pleaded fraud and tracing allegations, and the evidential basis for concluding that dissipation risk existed.
Finally, the case also raised procedural and doctrinal questions about how s 4(10) interacts with the court’s jurisdictional concepts. The court addressed the distinction between “power” to grant interim relief and “jurisdiction” to hear and determine the dispute, noting that the court must first have authority over the defendant and the dispute before it can decide whether it should exercise the injunctive power.
How Did the Court Analyse the Issues?
The court began by framing the issue as one of power rather than jurisdiction. Although some earlier cases used the language of “jurisdiction” in relation to s 4(10), the court explained that s 4(10 confers a discretionary power to grant interim injunctive relief where it appears just or convenient to do so. The court also clarified that “jurisdiction” in this context should be understood as the court’s authority to hear and determine a dispute brought before it. This distinction matters because the court must first be satisfied that it has properly assumed jurisdiction over the defendant and the claim, before it can decide whether to exercise its injunctive power.
On the state of the law, the court noted that there was a divergence of views in the High Court regarding the ambit of s 4(10). In Petroval SA v Stainby Overseas Ltd and others [2008] 3 SLR(R) 856, the plaintiff commenced a Singapore action solely to obtain interim relief, with the merits to be determined in another jurisdiction (the British Virgin Islands). The court in Petroval held that the Singapore court had no jurisdiction to grant a Mareva injunction in aid of foreign proceedings, reasoning that the substantive claim should terminate in a judgment by the court where the injunction is sought. The Petroval approach thus treated the foreign nature of the final determination as fatal to the grant of Mareva relief in Singapore.
By contrast, in Multi-Code Electronics Industries (M) Bhd and another v Toh Chun Toh Gordon and others [2009] 1 SLR(R) 1000, the High Court upheld a Mareva injunction granted in Singapore even though the underlying dispute was being litigated in Malaysia. The court in Multi-Code treated s 4(10) as conferring a residual jurisdiction/power over the underlying cause of action sufficient to ground the continuation of a domestic Mareva injunction against assets in Singapore, even if the Singapore action was stayed. However, the court set prerequisites: (a) the Singapore court must have in personam jurisdiction over the defendants; and (b) the stayed action must not have been struck out or set aside on the basis that there was no reasonable accrued cause of action or that the court lacked jurisdiction.
Against this background, the court in China Medical Technologies analysed whether s 4(10) could be invoked to grant Mareva relief in aid of foreign proceedings, particularly where the Singapore court had in personam jurisdiction over the defendant and the plaintiffs had a reasonable accrued cause of action recognisable in Singapore. The court also considered the concept of “justiciability” and the position in foreign jurisdictions, reflecting that interim relief in support of foreign proceedings is a recognised judicial function in some legal systems. The court ultimately concluded that the better view is that s 4(10) can be read to permit Mareva injunctions in aid of foreign proceedings, subject to the established Mareva requirements and the court’s discretion.
Having established the legal framework, the court turned to the evidence. It accepted that it had in personam jurisdiction over Bi because Bi was a Singapore citizen and had been properly served with the writ in Suit 1180. It was also not disputed that the plaintiffs had a reasonable accrued cause of action recognisable in Singapore, and that Bi had assets in Singapore that could be subject to the injunction. The focus therefore shifted to whether the plaintiffs had shown a good arguable case and a real risk of dissipation.
On the “good arguable case” requirement, the court assessed the allegations of fraud, the role attributed to Wu and Bi, and the plaintiffs’ tracing narrative linking funds from P1 and P2 to SW Payees and Further SW Payees, including accounts associated with Bi. The court also considered the relationship between Wu and Bi and the divorce agreement, which the plaintiffs relied on as part of the broader context for asset holding and potential movement. While the court did not decide the merits finally, it required a level of arguability sufficient to justify freezing relief.
On “real risk of asset dissipation”, the court examined whether there was evidence or reasonable inference that Bi would dissipate assets in Singapore to frustrate the foreign proceedings. Mareva relief is exceptional; the court therefore required more than speculation. It looked at the plaintiffs’ evidence of the alleged fraudulent scheme and the pattern of fund transfers, and whether that pattern suggested that Bi’s assets were likely to be moved or concealed if proceedings progressed. The court’s analysis was defendant-specific, recognising that even where a fraud is alleged against multiple persons, the risk assessment and arguability must be grounded in evidence linking each defendant to the relevant conduct and assets.
What Was the Outcome?
The High Court granted Mareva relief in Singapore in respect of the defendant(s) where the statutory and common law requirements were satisfied. The judgment indicates that the injunction against Wu had already been granted ex parte on 4 January 2018, while the application against Bi remained to be determined. The court’s ultimate orders reflected its conclusion that it had the power to grant Mareva injunctions in aid of foreign proceedings and that the plaintiffs met the requisite thresholds for the defendant(s) against whom the injunction was maintained or granted.
In practical terms, the decision enabled the plaintiffs to freeze assets in Singapore that were within the scope of the Singapore Mareva injunction, thereby supporting the effectiveness of the Hong Kong proceedings. The court also dealt with related procedural applications, including the plaintiffs’ application to stay Suit 1180 pending the final determination of the Hong Kong suits, while preserving the Singapore interim relief necessary to prevent dissipation.
Why Does This Case Matter?
This case matters because it clarifies the scope of s 4(10) of the Civil Law Act for Mareva injunctions sought in Singapore to support foreign litigation. For practitioners, the decision provides a structured approach: the court must have in personam jurisdiction over the defendant and the claim must be justiciable in Singapore; the plaintiffs must then satisfy the substantive Mareva requirements of a good arguable case and a real risk of dissipation. The court’s reasoning also helps reconcile earlier High Court divergence between Petroval and Multi-Code, offering guidance on when Singapore interim relief is appropriate even if the final merits are to be determined abroad.
From a litigation strategy perspective, China Medical Technologies demonstrates that Singapore can be used as a “freezing forum” where assets are located in Singapore and the defendant is amenable to Singapore process. This is particularly relevant in cross-border fraud and asset tracing cases, where defendants may move funds across jurisdictions and where foreign judgments or injunctions may not be immediately effective against assets held in Singapore.
For law students and researchers, the case is also useful for understanding how Singapore courts conceptualise “power” under s 4(10), the role of justiciability, and the evidential standards governing Mareva relief. The decision reinforces that Mareva injunctions are not granted as a matter of convenience or duplication; they require a disciplined assessment of arguability and risk, and they remain subject to the court’s discretion.
Legislation Referenced
- Civil Law Act (Cap 43, 1999 Rev Ed), s 4(10) [CDN] [SSO]
- British Columbia Law and Equity Act 1979
- Civil Jurisdiction and Judgments Act 1982
- Federal Courts Act 1985
Cases Cited
- [2018] SGCA 27
- [2018] SGHC 178
- Re Nalpon Zero Geraldo Mario [2013] 3 SLR 258
- Petroval SA v Stainby Overseas Ltd and others [2008] 3 SLR(R) 856
- Multi-Code Electronics Industries (M) Bhd and another v Toh Chun Toh Gordon and others [2009] 1 SLR(R) 1000
Source Documents
This article analyses [2018] SGHC 178 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.